Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

September 2013 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Modeling Immunity for Biodefense (MIB)

For the published request for applications, see the March 21, 2014, Guide announcement, Modeling Immunity for Biodefense (U19).

Atopic Dermatitis Research Network

For the published request for applications, see the March 20, 2014, Guide announcement, Atopic Dermatitis Research Network (ADRN) (U19).

Consortium of Food Allergy Research

For the published request for applications, see the February 26, 2014, Guide announcement, Consortium for Food Allergy Research (U19).

Adjuvant Development

Request for Proposals

Contact: Eileen Webster-Cissel

Objective: The goal of this project is to accelerate preclinical development of a single lead adjuvant candidate for preventing human disease caused by non-HIV disease pathogens.

Description: Adjuvants stimulate innate and/or adaptive immune responses. For the purpose of this SBIR, adjuvants are defined according to the FDA as “agents added to or used in conjunction with vaccine antigens to augment or potentiate (and possibly target) the specific immune response to the antigen.” The adjuvant products targeted in this program must be developed as components of antigen-specific vaccines against infectious disease and may not be developed as stand-alone agents. Currently, only two adjuvants have been approved for use in the U.S.—aluminum hydroxide/aluminum phosphate (alum) and 4’-monophosphoryl lipid A (MPL), a component of lipopolysaccharide adsorbed to alum. Additional efforts are needed to address limitations of current vaccine adjuvants and to more fully develop the potential capabilities of adjuvants.​

Last Updated March 24, 2014

Last Reviewed March 24, 2014